Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (NASDAQ: EYPT) has successfully closed its upsized public offering of 14,636,363 shares of common stock at $11.00 per share, including the full exercise of underwriters' option for additional 1,909,090 shares. The offering generated gross proceeds of approximately $161.0 million. The company plans to use the proceeds to advance clinical development of DURAVYU™ for wet AMD and DME, support early-stage pipeline initiatives, and for general corporate purposes. J.P. Morgan, Citigroup, and Guggenheim Securities served as joint book running managers.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the pricing of an upsized public offering of 12,727,273 shares of common stock at $11.00 per share, expecting to raise approximately $140.0 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to an additional 1,909,090 shares. The offering is expected to close around October 31, 2024. The proceeds will be used to advance clinical development of DURAVYU™ for wet AMD and DME, support pipeline development initiatives, and general corporate purposes.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a proposed public offering of $100 million of common stock shares, with an additional 30-day option for underwriters to purchase up to $15 million of shares. The offering, managed by J.P. Morgan, Citigroup, and Guggenheim Securities, aims to fund the clinical development of DURAVYU™ for wet AMD and DME treatments, support pipeline development, and general corporate purposes. The offering will be conducted under a previously filed S-3 registration statement.

EyePoint Pharmaceuticals announced positive interim 16-week data from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The DURAVYU 2.7mg demonstrated significant improvements with a gain of +8.9 letters in best-corrected visual acuity (BCVA) and a 68-micron reduction in central subfield thickness (CST) compared to baseline. The treatment showed a favorable safety profile with no DURAVYU-related serious adverse events. Notably, 82% of eyes in the DURAVYU 2.7mg arm remained supplement-free versus 50% in the aflibercept control arm at 16 weeks. The company expects to report full topline results in Q1 2025.

EyePoint Pharmaceuticals has dosed the first patient in its Phase 3 LUGANO clinical trial of DURAVYU™ for wet age-related macular degeneration (wet AMD). The trial, along with the upcoming LUCIA study, will evaluate DURAVYU's efficacy against aflibercept in approximately 400 patients globally. DURAVYU is administered every six months, compared to current treatments requiring frequent injections. The primary endpoint is measuring change in best corrected visual acuity at weeks 52 and 56. With over 150 clinical sites committed, the company expects topline data in 2026. The trials include both treatment-naïve and experienced patients, reflecting real-world populations.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the granting of non-statutory stock options to four new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan. These grants, approved by the Compensation Committee, are in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options, totaling 69,000 shares of EyePoint Pharmaceuticals common stock, were granted on October 15, 2024, with an exercise price of $9.88 per share.

The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years. Vesting is subject to continued service with the company.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee, comply with NASDAQ Listing Rule 5635(c)(4). Key details include:

• 43,000 shares of common stock options granted
• Grant date: September 13, 2024
• Exercise price: $9.10 per share (closing price on grant date)
• Ten-year term
• Vesting over four years: 25% after one year, remainder in monthly installments over three years
• Vesting contingent on continued employment

These inducement awards aim to attract and retain talent in EyePoint's mission to develop therapeutics for serious retinal diseases.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Fred Hassan, a distinguished industry leader, to its Board of Directors. This strategic move comes as the company prepares for the Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and future commercialization. Hassan, former CEO of three global pharmaceutical companies, brings extensive biopharmaceutical experience to EyePoint.

Simultaneously, Anthony P. Adamis, M.D. and David Guyer, M.D. have resigned from the Board due to their transition to full-time roles at Merck & Co. The company acknowledges their contributions in shaping EyePoint's product development pipeline and clinical strategies.

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in several upcoming investor conferences. These include:

• Morgan Stanley Annual Global Healthcare Conference (September 4, 2024)
• Baird Global Healthcare Conference (September 10, 2024)
• Cantor Global Healthcare Conference (September 18, 2024)
• UBS Virtual Ophthalmology Day (October 2, 2024)

The company will engage in various formats, including 1x1 investor meetings and fireside chats. Live webcasts and archived replays of the presentations will be available on the company's website.